Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $28

Benzinga · 2d ago
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $30 to $28.